NCT06299696View on ClinicalTrials.gov

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions
Cystic Fibrosis
Interventions
DRUG

VNZ/TEZ/D-IVA

FDC granules for oral administration

Trial Locations (1)

01801

Site 001, Woburn

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06299696 - A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists | Biotech Hunter | Biotech Hunter